A large analysis in melanoma patients treated with immune checkpoint inhibitors identified meaningful rates of nerve damage and suggested which patients may be at higher risk. The study reported that 12% developed significant neurotoxicity within about six months, with risk associated with pre-existing neuroinflammatory autoantibodies and T-cell gene signatures, sharpening attention on baseline immune profiling in practice.